Press Releases

Month Year

Month Year

Jun 28, 2021

Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial

- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants^1,2
Jun 17, 2021

Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)

* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
Jun 11, 2021

New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia

Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful
Jun 11, 2021

Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.
Jun 4, 2021

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

* Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research

Show per page

Print
Email page
RSS